Xinhao Ye | Director of CMC Management
WuXi Vaccines
Xinhao Ye has 15 years of vaccine development experience with growing responsibilities in research, development, and commercialization of different types of vaccines, including polysaccharide conjugate vaccines, recombinant protein, and mRNA-based vaccines. Before joining WuXi Vaccines, he worked at the Pfizer Vaccine Research Unit for 8 years and played key roles in various drug process development to advance clinical studies. He was a senior director of Design Pharmaceutical, leading R&D and a compound development team to accelerate drug discovery and development. Dr. Ye has published 15 peer-reviewed papers and book chapters with over 1,000 total citations up to date.
Appearances:
Day 2 - Wednesday 30th October @ 11:10
Transforming Vaccine Development and Manufacturing: Integrating Technology and Accessibility for a Healthier 21st Century
In the past century, vaccination has played a pivotal role in reducing mortality and morbidity caused by infectious diseases. Leveraging innovations from emerging technologies, vaccines are poised to meet evolving demands of a 21st-century society characterized by increased life expectancy, the emergency of new infections, and persistent poverty in low-income countries. Consequently, next-generation vaccines must be more effective, safer, and better tolerated across all ages, especially for children, the elderly, and other populations with compromised immune systems. Moreover, vaccine access and equality remain problematic in low- and middle-income countries (LMICs). Addressing this long-standing issue will require affordable vaccine supplies and local manufacturing capabilities. As a world-leading CRDMO, we will present how we get prepared and enable our clients, whether multinational corporations or biotech startups, to tackle these challenges. It includes comprehensive efforts to support structure-based immunogen design, accelerate novel vaccine development, enhance adjuvant accessibility and screening, and enable low-cost small-footprint manufacturing. Ultimately, the end-to-end platform aims to empower next-generation vaccine development, foster global collaboration, and support efforts in areas critical for epidemic and pandemic preparedness.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events